Patents by Inventor Luke Masterson

Luke Masterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210380605
    Abstract: A compound of formula (I) and salts and solvates thereof, wherein RL is a linker for connection to a cell binding agent, which is formula (IIa) wherein Q is a tripeptide residue of formula (A), where x is 1 or 2, —C(?O)-Qx-NH— is a dipeptide residue; X is: formula (B), where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5; and GL is a linker for connecting to a Ligand Unit.
    Type: Application
    Filed: October 18, 2019
    Publication date: December 9, 2021
    Inventors: Philip Wilson HOWARD, Ian HUTCHINSON, Luke MASTERSON
  • Publication number: 20210322401
    Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.
    Type: Application
    Filed: June 15, 2021
    Publication date: October 21, 2021
    Inventors: Philip Wilson HOWARD, Niall DICKINSON, Thais CAILLEAU, Luke MASTERSON, William GOUNDRY
  • Patent number: 11135303
    Abstract: A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; RL1 and RL2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R11 is either H, or R or, where Q is O, SO3M, where M is a metal cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: October 5, 2021
    Assignee: Medimmune Limited
    Inventors: John A. Flygare, Janet L. Gunzner-Toste, Thomas Pillow, Philip Wilson Howard, Luke Masterson
  • Publication number: 20210283141
    Abstract: A conjugate of formula I: wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain and each of RLL1 and RLL2 comprise the group:
    Type: Application
    Filed: May 24, 2019
    Publication date: September 16, 2021
    Inventors: Luke MASTERSON, Balakumar VIJAYAKRISHNAN, Ronald James CHRISTIE
  • Publication number: 20210187117
    Abstract: A conjugate of formula (I), wherein L is a Ligand unit, D is a Drug Linker unit of formula (II), wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R10 is OH, and R11 is formula (A): p is an integer of from 1 to 20.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 24, 2021
    Inventors: Philip Wilson Howard, Elizabeth Dunny, Luke Masterson
  • Publication number: 20200306243
    Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 1, 2020
    Inventors: Philip Wilson Howard, Niall Dickinson, Thais Cailleau, Luke Masterson, William Goundry
  • Publication number: 20200289660
    Abstract: A conjugate of formula I, wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.
    Type: Application
    Filed: November 13, 2018
    Publication date: September 17, 2020
    Inventors: Philip Wilson HOWARD, Luke MASTERSON, Thais CAILLEAU, Nazzareno DIMASI, Jason WHITE
  • Publication number: 20200247823
    Abstract: A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.
    Type: Application
    Filed: August 17, 2018
    Publication date: August 6, 2020
    Inventors: Nazzareno DIMASI, Philip Wilson HOWARD, Luke MASTERSON, Arnaud Charles TIBERGHIEN, Balakumar VIJAYAKRISHNAN, Jason WHITE
  • Patent number: 10695439
    Abstract: A conjugate of formula (I): L-(DL)p (I) wherein L is a Ligand unit, D is a Drug Linker unit of formula (II) wherein p is an integer of from 1 to 20.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 30, 2020
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Luke Masterson
  • Publication number: 20200157240
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 21, 2020
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Patent number: 10533058
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: January 14, 2020
    Assignees: Genentech Inc., Medimmune Limited
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben, Philip Wilson Howard, Luke Masterson
  • Publication number: 20190125893
    Abstract: A conjugate of formula (I): L-(DL)p (I) wherein L is a Ligand unit, D is a Drug Linker unit of formula (II) wherein p is an integer of from 1 to 20.
    Type: Application
    Filed: February 10, 2017
    Publication date: May 2, 2019
    Inventors: Philip Wilson Howard, Luke Masterson
  • Publication number: 20180134717
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Application
    Filed: October 4, 2017
    Publication date: May 17, 2018
    Inventors: Philip Wilson HOWARD, Luke Masterson, Arnaud Tiberghien, John A. Flygare, Janet L. Gunzner, Paul Polakis, Andrew Polson, Helga E. Raab, Susan D. Spencer
  • Publication number: 20170290920
    Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 12, 2017
    Applicants: MEDIMMUNE LIMITED, GENENTECH, INC.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, John A. Flygare, Janet L. Gunzner-Toste, Thomas H. Pillow, Philip Wilson Howard, Luke Masterson
  • Patent number: 9732084
    Abstract: Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 15, 2017
    Assignees: Medimmune Limited, Seattle Genetics Inc.
    Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke, Peter Senter
  • Patent number: 9624227
    Abstract: A compound with the formula I:
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: April 18, 2017
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Stephen John Gregson, Luke Masterson
  • Publication number: 20160310611
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: December 16, 2014
    Publication date: October 27, 2016
    Applicants: Genentech Inc., Medimmune Limited
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Publication number: 20150111880
    Abstract: A compound with the formula I: wherein: R2 is of formula II: where A is a C5-7 aryl group, X is selected from the group comprising: OH, SH, CO2H, COH, N?C?O, NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl, and (OC2H4)mOCH3, where m is 1 to 3, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and is from 1 to 3; or (ii) Q1 is —CH?CH—, and Q2 is a single bond; R12 is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR?, nitro, Me3Sn and halo; either: (a) R10 is H, and R
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Philip Wilson Howard, Stephen John Gregson, Luke Masterson
  • Patent number: 8940733
    Abstract: The present invention is directed to novel pyrrolobenzodiazepine dimers and methods of using the dimers in the treatment of proliferative diseases.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: January 27, 2015
    Assignee: Spirogen SARL
    Inventors: Philip Wilson Howard, Stephen John Gregson, Luke Masterson
  • Patent number: 8829184
    Abstract: A compound of formula (I): which is substantially free of any of the corresponding compound of formula (IB): methods of making such compounds, and the further transformation of such compounds.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: September 9, 2014
    Assignee: Spirogen SARL
    Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien